GREAT NECK, N.Y.--(BUSINESS WIRE)-- Neogenix Oncology, Inc. (Neogenix) announced today that researchers at Duke University Medical Center have received approval to move forward with a Phase I trial of the company’s lead therapeutic antibody, NPC-1C, in patients with advanced stage pancreatic or colorectal cancer. Duke joins Johns Hopkins Hospital which is already conducting the Phase I trial of NPC-1C. In addition to Johns Hopkins, North Shore - LIJ has also enrolled patients on this multi-center study.
NPC-1C is a novel, chimeric monoclonal antibody intended for the treatment of advanced pancreatic and colorectal cancer, and is the first of the Neogenix pipeline of antibodies that target specific cancers. Pre-clinical studies have demonstrated that NPC-1C specifically targets pancreatic and colorectal cancer sparing healthy tissue.
“We are pleased to partner with the investigators at Duke University Medical Center as they join Johns Hopkins on this study. We look forward to fostering the relationships with both of these prestigious medical establishments for future Neogenix therapeutic development. There is a serious need for new therapies for life-threatening cancers, especially pancreatic cancer where very few treatment options exist. Having a treatment that would target the cancer specifically and spare healthy organs would represent a significant advancement in the treatment of this disease”, said Neogenix Chief Executive Officer, Philip M. Arlen, MD.
"I am pleased to be participating in the clinical evaluation of this agent in a study population with limited treatment options,” said Michael A. Morse, M.D., associate professor of medicine at Duke University Medical Center, Principal Investigator on the study.
About Neogenix Oncology
Neogenix Oncology is a development stage biotechnology company focused on developing and commercializing therapeutic and diagnostic products for the early detection and treatment of pancreatic, colorectal, lung, cervical, ovarian, prostate, and other cancers. The company’s portfolio includes monoclonal antibodies that are designed to be specific to cancer cells by recognizing epitopes that are tumor specific, that is, found on cancer cells, but not normal cells. Founded in late 2003 and headquartered in Great Neck, NY, the company conducts its research and development work in its laboratories in Rockville, MD. The company is presently conducting a clinical study to establish certain of its antibodies as a serum diagnostic for pancreatic and colorectal cancers, and in December 2009 began a multicenter Phase I therapeutic trial to evaluate the clinical safety of the NPC-1C antibody in patients with metastatic pancreatic and colorectal cancer.
Forward Looking Statements
Certain statements contained in this release are forward-looking statements that relate to future events. These statements are based on current expectations only and are subject to known and unknown risks, uncertainties and other factors which may cause the actual results to be materially different from any future results express or implied by such forward-looking statements, including those risk factors discussed in the company’s SEC reports, including the company’s Form 10 and quarterly reports on Form 10-Q. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
RMT PR Management
RoseMarie Terenzio, 212-414-1909
KEYWORDS: United States North America New York
INDUSTRY KEYWORDS: Health Biotechnology Clinical Trials Oncology